Related references
Note: Only part of the references are listed.Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence
J. McAllister et al.
HIV MEDICINE (2014)
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)
Massimiliano Fabbiani et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2014)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
Hans-Juergen Stellbrink et al.
AIDS (2013)
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
Allison Martin et al.
AIDS (2013)
Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study
Kathleen E. Squires et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
Next-Generation Integrase Inhibitors Where to After Raltegravir?
Sharon L. Karmon et al.
DRUGS (2013)
Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults
Frederick J. Lee et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Andrew Zolopa et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Juergen K. Rockstroh et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
Richard Elion et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK
Juergen K. Rockstroh et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study
Polyana Monteiro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Joseph J. Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
After first-line ART: towards an evidence-based SECOND-LINE
Alessandro Soria et al.
LANCET (2013)
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn et al.
LANCET (2013)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
Francois Raffi et al.
LANCET INFECTIOUS DISEASES (2013)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J. Eron et al.
LANCET INFECTIOUS DISEASES (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial
Takeshi Nishijima et al.
PLOS ONE (2013)
Could better tolerated HIV drug regimens improve patient outcome?
Mikaela Smit et al.
AIDS (2012)
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study
Giordano Madeddu et al.
AIDS (2012)
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
Esteban Martinez et al.
AIDS (2012)
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
Adrian Curran et al.
AIDS (2012)
A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naive HIV-Infected Patients: SPARTAN Study Results
Michael J. Kozal et al.
HIV CLINICAL TRIALS (2012)
Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence
Kenneth H. Mayer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)
Eduardo Gotuzzo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus et al.
LANCET (2012)
The future of integrase inhibitors of HIV-1
Isabelle Malet et al.
CURRENT OPINION IN VIROLOGY (2012)
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
Alain Nguyen et al.
AIDS (2011)
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Joseph J. Eron et al.
LANCET INFECTIOUS DISEASES (2011)
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
Esteban Martinez et al.
AIDS (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
Jose M. Gatell et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C
Eugenia Vispo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Joseph J. Eron et al.
LANCET (2010)
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
Y. Yazdanpanah et al.
CLINICAL INFECTIOUS DISEASES (2009)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
M. Iwamoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Share Paper
